Alibaba Sues Pentagon Over 188-Entity Military Blacklist
Alibaba sued the Pentagon in San Jose on June 23, claiming its Section 1260H designation violates due process, with a DoD contract ban due June 30.
Alibaba sued the Pentagon in San Jose on June 23, claiming its Section 1260H designation violates due process, with a DoD contract ban due June 30.
World Leaks posted 200,000 files from Tata's breach, including Apple iPhone schematics and PCB designs. Dell and Nike were the warm-up.
A new executive order moves the post-quantum crypto deadline for high-value federal systems from 2035 to 2030, five years faster than planned.
Walmart's undisclosed Vibe.co deal plugs the SMB gap in its CTV stack, coming one day after it unified ad ops across Walmart Connect and Sam's Club.
Lilly converts a $1.4B milestone obligation into a $50M clean platform buy; Sangamo's Chapter 11 shows how bankruptcy reshapes deal math.
Jubair, 20, faces a US indictment over 120 intrusions and $115M in ransom, but the UK's six-week trial never made it past opening arguments.
Anthropic starts scanning government IDs on July 8. Consumers face biometric checks, but the API exemption reveals the real dividing line.
Exelixis' zanzalintinib missed OS in the NLM subgroup, putting roughly half of a $1.3B peak-sales estimate at stake before the Dec. 3 FDA call.
LSD-based DT120 beat placebo by 8.1 MADRS points and held the gain through week 12. Definium's FDA submission just got a lot more credible.
OCC's Bank Secrecy Act rule for stablecoin issuers arrived the same week five agencies jointly proposed mandatory KYC for the same companies.
With the CFPB retreating, NJ AG Davenport's $20K-per-violation junk-fee blueprint may hand every state AG a ready-made enforcement map.
Nuvectis paid $40M upfront for ex-China rights to Haisco's once-daily Factor B inhibitor in a PNH market projected above $5B in 2026.
Polymarket staged $900K in fake wins for banned US users using copycat sites and a hired creator network. Its second marketing scandal in three weeks.
SK Biopharmaceuticals is putting $18M upfront on a $2.5B Insilico neuroimmune deal — and the backloaded structure tells you who blinked.
Four state AGs are probing FIFA's World Cup tickets: seat bait-and-switch, sky-high variable pricing, and no consumer disclosure framework.